The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
Authors:
- 15 June 2023
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 37 (6) , 1201-1214
Abstract
No abstract availableKeywords
Funding Information
- NCI
- Leukemia & Lymphoma Society
This publication has 43 references indexed in Scilit:
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsScience Translational Medicine, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017
- Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell KillingCancer Cell, 2017
- Targeting B-Cell Maturation Antigen in Multiple MyelomaImmunotherapy, 2015
- Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancerBlood, 2012